Teleflex Incorporated filed a Form 8-K with the SEC on September 9, 2026, disclosing that its Board of Directors elected Sean M. Salmon as a new director, effective September 8, 2026, expanding the board from eight to nine members.

Key Highlights

  • Board size increased: The Board approved an expansion from eight to nine directors, creating the vacancy Mr. Salmon was elected to fill.
  • New director appointed: Sean M. Salmon, age 61, was elected to the Board on September 8, 2026, upon recommendation of the Nominating and Governance Committee.
  • Committee assignment: Mr. Salmon was also appointed to the Growth and Operating Committee of the Board.
  • Current occupation: Mr. Salmon currently provides business and strategic consulting through Zamboni Holdings, LLC, a firm he founded in December 2025.
  • Medtronic background: Prior to founding his consulting firm, Mr. Salmon held a 21-year career at Medtronic plc, most recently serving as Executive Vice President and President, Cardiovascular from January 2021 to September 2025.
  • Compensation terms: Mr. Salmon will receive compensation consistent with that provided to all non-employee directors, as described on pages 15 to 17 of the Company's proxy statement filed April 13, 2026.
  • No related-party transactions: The filing states there are no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

Teleflex Board Election of Sean M. Salmon: Background and Terms

According to the filing, Teleflex Incorporated (NYSE:TFX) disclosed that its Board of Directors, acting on the recommendation of the Nominating and Governance Committee, voted on September 8, 2026, to increase the board from eight to nine directors and simultaneously elected Sean M. Salmon to fill the newly created seat. The company also appointed Mr. Salmon to its Growth and Operating Committee.

The filing describes Mr. Salmon, age 61, as the founder of Zamboni Holdings, LLC, a consulting firm he established in December 2025 through which he currently provides business and strategic consulting and advisory services. Before launching that firm, Mr. Salmon spent 21 years at Medtronic plc, where he held several executive roles. These included Executive Vice President and President, Cardiovascular (January 2021 to September 2025); Executive Vice President and President, Cardiovascular and Diabetes (December 2020 to May 2022); Executive Vice President and President, Diabetes (October 2019 to December 2020); and President, Coronary and Structural Heart Business Units (July 2014 to October 2019), among other senior positions dating to November 2004. Prior to Medtronic, the filing notes he held positions at C.R. Bard, Inc. and Johnson and Johnson. Mr. Salmon currently serves as a director of Adagio Medical Holdings, Inc., according to the filing.

The filing states that Mr. Salmon's compensation will be consistent with that currently provided to all Company non-employee directors, as described on pages 15 to 17 of the Company's proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 13, 2026. The filing further states that "there are no arrangements or understandings" between Mr. Salmon and the Company or any other persons pursuant to which he was selected as a director.

What Was Disclosed

Teleflex reported the election of Sean M. Salmon to its Board of Directors and his appointment to the Growth and Operating Committee, effective September 8, 2026, along with a board size increase from eight to nine directors and confirmation of standard non-employee director compensation terms.